Canadian Cardiovascular Pharmacists Network

Save the date! May 2, 2020 23rd Annual Contemporary Therapeutics Issues in Cardiology Toronto, ONSave the date! May 2, 2020 23rd Annual Contemporary Therapeutics Issues in Cardiology Toronto, ON

AFIRE: AF + stable CAD; rivaroxaban +/- antiplatelet agent; terminated early secondary to increase all cause mortality and bleeding in combination arm. Unexpected results. https://www.nejm.org/doi/full/10.1056/NEJMoa1904143

Dont forget to register for our Western conference: https://sites.google.com/view/ccpnwestern2019/program Register online by Sept 15, 2019: ccpnfall2019.eventbrite.ca

Guidelines for the management of heart failure by pharmacists. Great practical tips. https://journals.sagepub.com/doi/10.1177/1715163519853307

Check out our Western Conference line up: https://sites.google.com/view/ccpnwestern2019/program Register online by Sept 15, 2019: ccpnfall2019.eventbrite.ca

Great article on the ins and outs of ASA in primary prevention and the evidence to date https://www.thelancet.com//PIIS0140-6736(19)3054/fulltext

Apixiban in extremes of body weight: post-hoc analysis from the ARISTOTLE trial: https://www.ahajournals.org//10/CIRCULATIONAHA.118.037955

Not available in Canada yet, but likely on the horizon. Andexanet Alfa for bleeding associated with Factor Xa Inhibitors (ANNEXA-4): https://www.nejm.org/doi/pdf/10.1056/NEJMoa1814051

Looking to advance your skills in cardiology? Check out this course offered by the University of Toronto for pharmacists: https://learn.utoronto.ca//3577-advanced-cardiology-pharma

Nice review on congestion in heart failure and diuretics. https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.1369

TRED-HF: In patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered, many patients will relapse following treatment withdrawal. Bottomline: Treatment should continue indefinitely. https://www.thelancet.com//PIIS0140-6736(18)32484/fulltext

Hypertension Canada is in Edmonton this year. Sept 25 -28, 2019. This years theme "A Whole Patient Approach" https://hypertension.ca/congress/ @HTNCanada

Looking to refine your skills and knowledge in cardiology? Consider a Year 2 Residency in Cardiololgy: https://www.cshp.ca/alberta-health-services-cardiology-prog

Looking for a focused cardiology conference in Banff? Look no more. Mar 10-13, 2019: https://accrockies.com/

New guidelines on the management of bradycardia: http://www.onlinejacc.org//e/2018/10/29/j.jacc.2018.10.044

Newly updated definitions of myocardial infarction: https://www.acc.org//fourth-universal-definition-of-mi-esc

AVERT Trial: Apixiban 2.5mg BID prevents thromboembolism (NNT=17 over 180 days) in intermediate to high risk ambulatory cancer patients receiving chemotherapy but increases bleeding (NNH = 59 ) when compared to placebo.

VITAL Study: Vitamin D and CV Events - no effect on CV outcomes https://www.nejm.org/doi/full/10.1056/NEJMoa1809944

Just when you finally figured out the anti-arrhythmic classification system. Spoiler alert: It just got more complicated. https://www.ahajournals.org//10./CIRCULATIONAHA.118.035455

PARAMEDIC2: Higher 30 day survival with epinephrine for out of hospital cardiac arrest, but more severe neurologic impairment in survivors https://www.nejm.org/doi/pdf/10.1056/NEJMoa1806842

Overwhelmed by so many CV guidelines? Check out these harmonized Canadian guidelines: http://www.cmaj.ca/content/190/40/E1192

Canadian consensus document on the treatment of cancer related thrombosis: http://www.current-oncology.com//oncology/article/view/4266 @CurrentOncology @CAPhO_ACPhO #thrombosis

New 2018 Canadian Guidelines on Familial Hypercholesterolemia: https://www.onlinecjc.ca/ar/S0828-282X(18)31171-1/fulltext

Did you know that rivaroxaban can now be used in patients with a CrCl as low as 15 mL/min. Check out our newly updated app: https://itunes.apple.com/ca/app/ccpn-spaf-tool/id913300357

Interesting study looking at propranolol vs. metoprolol for electric storm http://www.onlinejacc.org/content/71/17/1897

Hot off the press: 2018 Focused Update of CCS guidelines for the management of Atrial Fibrillation: https://www.onlinecjc.ca/art/S0828-282X(18)31062-6/fulltext

Nice summary of the ARTEMIS study (Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study): https://www.youtube.com/watch?v=7Xdg_l8OPq8

Only 10 days left till our Fall Symposium in Edmonton. Registration closes Sept 20th. https://www.eventbrite.ca/e/17th-annual-cardiovascular-fall

Only 28 days until our 17th Annual Cardiovascular Fall Symposium in Edmonton. Dont forget to register. Spots are limited! 17th Annual Cardiovascular Fall Symposium -- https://www.eventbrite.ca/e/17th-annual-cardiovascular-fall

Ascend (n-3 Fatty Acid) published. No benefit of n-3 Fatty Acids in primary prevention of patients with diabetes. https://www.nejm.org/doi/full/10.1056/NEJMoa1804989?query=RP

ASCEND (ASA) published. Primary prevention of low dose ASA in patients with diabetes showed a small reduction in CV events (NNT = 100 over 7.4 yrs) and increase risk of bleeding (NNH = 100 over 7.4 yrs). Benefit counterbalanced by risk overall. https://www.nejm.org/doi/full/10.1056/NEJMoa1804988?query=RP

COMMANDER HF published. No benefit to anticoagulation in HFrEF + CAD without atrial fibrillation. https://www.nejm.org/doi/full/10.1056/NEJMoa1808848?query=RP

Program details for our upcoming conference in Edmonton https://sites.google.com/ualberta.ca/ccpn-western/program